Pfizer pays Starna $330 million upfront
Pfizer paid $330 million upfront and gained exclusive rights to three preclinical programs treating autoimmune diseases using in vivo cell therapy.
- Field
- industry news
- What they did
- Pfizer signed an agreement with Starna Therapeutics to gain exclusive rights to three preclinical programs for treating autoimmune diseases using 'in vivo' cell therapy.
- Why it matters
- Pfizer will pay $330 million upfront and receive additional payments for reaching development and commercial milestones, expanding their pipeline.
#car-t#in vivo#cell therapy#pfizer#starna therapeutics



